Viktor Grünwald is a professor for Interdisciplinary Urooncology at the University Hospital Essen. Professor Grünwald specialises in Internal Medicine and Medical Oncology. His main areas of research interest are in renal cell carcinoma, soft tissue sarcomas, head and neck cancers, with an emphasis on the development of molecular and immunotherapies. Prof Grünwald graduated from the Medical School Hannover in 1998, after which he was appointed as a Private Lecturer in Haematology and Oncology at the same institution. He became professor for Haematology and Oncology at the Medical School Hannover in 2014. Professor Grünwald was appointed to the steering committee for genitourinary (GU) cancers (non-prostate) at the ESMO and ESMO ASIA Congress and is part of scientific committees of the International Kidney Cancer Symposium (EIKCS), German Cancer Congress (DKK) and the German Society for Hematology and Oncology (DGHO). He has co-chaired the Phase 3 Working Group of the Central European Society of Anticancer Drug Research (CESAR) studies group and a former member of the board of the German Medical Oncology studies group (AIO). Prof. Grünwald chairs the AIO Head and Neck (SCCHN) Working Group and within the AIO he is the former spokesman of the Sarcoma (STS) Working Group. Within the German Cancer Society, he chairs the Working Group for renal tumors (RCC) and is co-chair of the interdisciplinary head and neck tumors group. He chairs the ESMO preceptorship on SCCHN and is part of the faculty of the ECCO-AACR-EORTC-ESMO workshop on methods in clinical cancer research. His current trial proposals explore novel concepts in RCC, STS and SCCHN, focusing on translational research and drug development of immunotherapies in these indications.

Prof. Viktor Grünwald has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

Bayer and Roche.